Laureate Pharma Company – Press Release

FOR IMMEDIATE RELEASE

Laureate Pharma Launches New Contract Manufacturing Venture

Company offers services for development and manufacture of biopharmaceuticals and sustained-release products


Princeton, NJ – May 21, 2002 – Laureate Pharma Company announces the launch of contract manufacturing services at its two sites in New Jersey. Biopharmaceutical development and manufacturing services will be provided at a cGMP manufacturing facility in Princeton, NJ. Services related to sustained release microsphere products will be provided at its second manufacturing site in Totowa, NJ.

“We are very excited about our entry into the contract-services business“, says Robert J. Broeze, Ph.D., who was recently appointed President of the company. “We will play a significant role in meeting the pharmaceutical industry’s demand for manufacturing capacity and expertise in two very active areas: biopharmaceutical and sustained-release pharmaceuticals.” Dr. Broeze has over 20 years experience in the biopharmaceutical industry with emphasis on development and manufacture of biopharmaceutical products.

Laureate Pharma’s biopharmaceutical division, located in Princeton, NJ, provides a wide range of product development services from process design and development to full-scale cGMP production, purification and aseptic filling, as well as corresponding analytical services and regulatory support. The company will utilize its 200 and 2,000-liter stirred-tank bioreactors and hollow-fiber bioreactors for production of biopharmaceutical products expressed by mammalian cells. The division is focused on two extremely active segments of the biopharmaceutical industry: monoclonal antibody and recombinant protein products.

Laureate Pharma’s microsphere division, located in Totowa, NJ, provides services for development and manufacture of sustained-release micro-particle formulations of drugs and biopharmaceutical products. Its commercial scale manufacturing facility focuses on products where benefit would be achieved by sustained release. The company also offers comprehensive process development programs to advance products from early stage development through full-scale cGMP manufacturing.

Michiel E. Ultee, Ph.D., Senior Director of Biopharmaceutical Development & Operations, adds, “The solid and combined expertise of our team, along with our modern cGMP-compliant facilities, uniquely positions us as the new supplier of choice for both clinical-scale processing of protein therapeutics from mammalian cells and also for commercial-scale production of sustained-release microsphere products.” Dr. Ultee, responsible for Laureate Pharma’s biopharmaceutical development and manufacturing operations, joins the company with over 15 years experience in this area. Other members of the company’s management team include Mary-Joan Hampson-Carlin, Executive Director of Quality Services, and Robert P. Morgan, P.E., Senior Director of Facilities Engineering. Rounding out the management team is Ernest R. Tyler, Senior Director, Parenteral Production, with responsibility for the company’s microsphere manufacturing operations. Mr. Tyler has over 30 years experience in development of sustained release products, medical device manufacturing and bio-tech development.

Laureate Pharma is a privately held contract manufacturing services company. The company is dedicated to supporting the development and commercialization of products for pharmaceutical and biopharmaceutical companies. For more information on Laureate Pharma, contact the company directly at 609-919-3400, by email at support@laureatepharma.com or visit www.laureatepharma.com

For editorial information contact Horst Tuckow, Techmarketing, Inc., 150 Boulevard, Mt. Lakes, NJ 07046
Phone: (973) 402-6060 X12 Fax: (973) 402-6783 email: horstpt@tmteam.com